Sterne Agee Lowers Rating On Cigna
Sterne Agee lowered its rating on Cigna Corporation (NYSE: CI) from Buy to Neutral in a report issued Tuesday with a $110 price target.
Analyst Brian Wright continued to "view CI's international assets as under appreciated," however, he was "increasingly concerned about the company's ability to achieve either its commercial MCR or Medicare MCR targets and are thus lowering our rating to Neutral from Buy on elevated execution risk in 2H14."
Wright also noted that "following 2Q14 reports, we lowered our 2014 EPS estimate to $7.10, which is well below the $7.37 consensus estimate as a result of medical care ratio (MCR) pressures in both its guaranteed cost and Medicare businesses in 2Q14."
The report conclude that "the guaranteed cost MCR deteriorated 690 bps year over year in 2Q14 and cost trend commentary has subtly changed. Taken in conjunction with Aetna's recent commentary about outpatient cost trend coming in at the higher end of the previously expected range, we are being more sensitive to such subtleties."
Cigna Corporation recently traded at $86.94, down 0.93 percent.
Latest Ratings for CI
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | Mizuho | Maintains | Buy | |
Feb 2022 | SVB Leerink | Maintains | Market Perform | |
Feb 2022 | Morgan Stanley | Maintains | Equal-Weight |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Brian Wright Sterne AgeeAnalyst Color Downgrades Price Target Analyst Ratings